At the end of the latest market close, Kintara Therapeutics Inc. (KTRA) was valued at $2.50. In that particular session, Stock kicked-off at the price of $2.48 while reaching the peak value of $2.48 and lowest value recorded on the day was $2.25. The stock current value is $2.31.
Recently in News on February 17, 2021, Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Recurrent GBM. Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has enrolled the final patient in the recurrent arm of its ongoing Phase 2 clinical study of VAL-083 being conducted at the MD Anderson Cancer Center (MD Anderson). The recurrent arm of the study addresses patients suffering from glioblastoma multiforme (GBM) who have been pre-treated with temozolomide (TMZ) prior to disease recurrence. The trial was designed to enroll up to 83 patients (35 patients at 40 mg/m2/day and 48 patients at 30mg/m2/day) to determine whether treatment with VAL-083 improves overall survival. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Kintara Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.35 on 02/10/21, with the lowest value was $1.26 for the same time period, recorded on 01/04/21.
Kintara Therapeutics Inc. (KTRA) full year performance was 261.22%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Kintara Therapeutics Inc. shares are logging -31.04% during the 52-week period from high price, and 507.89% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.38 and $3.35.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1146077 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Kintara Therapeutics Inc. (KTRA) recorded performance in the market was 80.47%, having the revenues showcasing 46.20% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 76.60M, as it employees total of 4 workers.
Specialists analysis on Kintara Therapeutics Inc. (KTRA)
During the last month, 0 analysts gave the Kintara Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.59, with a change in the price was noted +0.92. In a similar fashion, Kintara Therapeutics Inc. posted a movement of +66.19% for the period of last 100 days, recording 804,014 in trading volumes.
Trends and Technical analysis: Kintara Therapeutics Inc. (KTRA)
Raw Stochastic average of Kintara Therapeutics Inc. in the period of last 50 days is set at 50.24%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 40.57%. In the last 20 days, the company’s Stochastic %K was 47.81% and its Stochastic %D was recorded 49.24%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 80.47%. Additionally, trading for the stock in the period of the last six months notably improved by 72.39%, alongside a boost of 261.22% for the period of the last 12 months. The shares increased approximately by -10.47% in the 7-day charts and went down by 23.53% in the period of the last 30 days. Common stock shares were driven by 46.20% during last recorded quarter.